The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Key targets and the future of immunotherapy in AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, outlines the role of immunotherapy in the treatment of acute myeloid leukemia (AML), highlighting data on PD-L1 and anti-CTLA4 immune checkpoint inhibitors and novel immunotherapies such as the CD47-targeted antibody magrolimab, which has shown promising data in combination with azacitidine in patients with high-risk myelodysplastic syndromes (MDS) and AML. Dr Wang also comments on the use of anti-TM3 and anti-CD7 antibodies, bispecific antibodies and flotetuzumab, as well as the potential to find therapies which can achieve undetectable measurable residual disease in AML. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
